Risk-benefit assessment of ivabradine in the treatment of chronic heart failure

Overview of attention for article published in Drug, Healthcare and Patient Safety, April 2014

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis

Article in International Journal of Clinical Pharmacy (January 2019)

Ivabradine (Corlanor) for Heart Failure: The First Selective and Specific I f Inhibitor.

Article in P & T : a peer-reviewed journal for formulary management (December 2015)

Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors

Article in Future Oncology (July 2015)